HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology
Retrieved on:
Thursday, January 6, 2022
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, NASH, Therapy, University, Fatty liver disease, Chronic liver disease, Roy Taylor (scientist), Lists of diseases, Patient, Primary biliary cholangitis, IND, T2DM, Chen Jin, Pharmacology, Buffalo, NAFLD, PSC, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Degenerative disease, SVP, Institute of Liver and Biliary Sciences, Drug, Clinical pharmacology, Amgen, State, Primary sclerosing cholangitis, HighTide, State university system, PBC, NDA, Pharmaceutical industry, Novartis
HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.
Key Points:
- HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.
- Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development.
- Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio, renal, metabolic, and liver diseases.
- We are very pleased to welcome Jin to the HighTide team, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.